S&P 500
5,844.61
-1.6%
-95.85
DJI
41,860.44
-1.9%
-816.80
NASDAQ
$18,872.64
-1.4%
-$270.07
Bitcoin
111,434.00
+3.9%
+4,196.42
AAPL
$202.42
-2.1%
-$4.44
AMZN
$201.35
-1.3%
-$2.72
GOOG
$170.25
+3.0%
+$4.93
META
$635.69
-0.2%
-$1.41
MSFT
$453.22
-1.1%
-$4.95
NVDA
$131.94
-1.8%
-$2.44
TSLA
$334.80
-2.6%
-$9.02
Citius Pharmaceuticals (NASDAQ: CTXR)
$0.67
(-9.7%)
-$0.07
Price as of May 21, 2025, 2:48 p.m. ET
Citius Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Citius Pharmaceuticals Company Info
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
News & Analysis
Featured Article
Could Citius Pharmaceuticals Be a Millionaire-Maker Stock?
A lot would have to go right for this biotech to make investors rich.
Alex Carchidi | Jul 20, 2021
Featured Article
Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today
Another interim analysis has come and gone with an unsatisfying result.
Cory Renauer | Jul 1, 2021
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.